Unexpected Tumor Regression After Recombinant Human Thyroid-Stimulating Hormone Administration
AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 689-692
DOI: 10.1016/j.aed.2026.04.013 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Ricaurte Crespo-Trevino und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota.
Zitieren
APA
Crespo-Trevino, R., & Hallanger-Johnson, J. (2026). Unexpected Tumor Regression After Recombinant Human Thyroid-Stimulating Hormone Administration. AACE Endocrinology and Diabetes, 13(5), 689-692. https://doi.org/10.1016/j.aed.2026.04.013
Vancouver
Crespo-Trevino R, Hallanger-Johnson J. Unexpected Tumor Regression After Recombinant Human Thyroid-Stimulating Hormone Administration. AACE Endocrinology and Diabetes. 2026;13(5):689-692. doi:10.1016/j.aed.2026.04.013
BibTeX
@article{CrespoTrevino2026,
author = {Crespo-Trevino, Ricaurte and Hallanger-Johnson, Julie},
title = {Unexpected Tumor Regression After Recombinant Human Thyroid-Stimulating Hormone Administration},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {5},
pages = {689--692},
doi = {10.1016/j.aed.2026.04.013}
}
EUVIMED